[ad_1]
The candidate coronavirus vaccine developed by AstraZeneca Plc and the University of Oxford appears to elicit a strong immune response in the elderly, in the hope that it can protect those who are most vulnerable to the disease.
According to Reuters, the data shows that people over the age of 70 – that is, those who are at higher risk of becoming seriously ill with Covid-19 and at risk of death – could develop strong immunity to the coronavirus, the researchers said.
The data was partially published last month, but was published in full and officially in The Lancet medical journal today, Thursday (11/19).
“The strong antibody and T-cell responses seen in the elderly in our study are encouraging,” said Maheshi Ramasamy, consultant and co-principal investigator for the Oxford Vaccine Group.
“People most at risk for COVID-19 include people with pre-existing health conditions and the elderly. We hope that our vaccine will help protect some of the most vulnerable people in society, but more research is needed to be sure.” added.
In Phase 3 of the experimental vaccine, tests are performed to confirm the findings and to verify whether the vaccine protects against SARS-CoV-2 infection in a wide range of people, including people with underlying diseases.
AstraZeneca’s candidate vaccine, called AZD1222 or ChAdOx1 nCoV-19, has been at the forefront of global efforts to develop coronavirus vaccines.
However, competing pharmaceutical companies such as Pfizer Inc, BioNTech, and Moderna Inc. have made progress in the last 10 days, giving promising results from vaccine trials, showing efficiencies of 90% to 95%.
Unlike the Pfizer-BioNTech and Moderna candidate vaccines, which use a new technology known as messenger RNA (mRNA), the AstraZeneca experimental vaccine is produced from an attenuated version of a common cold virus found in chimpanzees. .
In Phase 3 of your experimental vaccine AstraZeneca participated 560 healthy volunteers, of whom 160 were between 18 and 55 years old, another 160 were between 56 and 69 years old and 240 were 70 years or older.
The volunteers received two doses of the vaccine or a placebo, and no serious side effects associated with the AZD1222 vaccine were reported, the researchers said.
AstraZeneca has entered into several supply and manufacturing agreements with companies and governments around the world as it approaches to report the results of its final vaccine trials.
Read them News of Greece and the world, with its reliability and validity News247.gr.
window.fbLoaded = $.Deferred();
window.fbAsyncInit = function(){ FB.init({ appId: "767480436596774", xfbml: true, version: "v3.3" }); window.fbLoaded.resolve(); };
(function(d, s, id){ var js, fjs = d.getElementsByTagName(s)[0]; if (d.getElementById(id)) {return;} js = d.createElement(s); js.id = id; js.src = "https://connect.facebook.net/en_US/all.js"; fjs.parentNode.insertBefore(js, fjs); }(document, 'script', 'facebook-jssdk'));
[ad_2]